HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
出版年份 2020 全文链接
标题
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
作者
关键词
-
出版物
EMBO Molecular Medicine
Volume 12, Issue 5, Pages -
出版商
EMBO
发表日期
2020-04-24
DOI
10.15252/emmm.201911498
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- An auristatin‐based antibody‐drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer
- (2019) Laura Bourillon et al. INTERNATIONAL JOURNAL OF CANCER
- TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells
- (2019) Elena Díaz-Rodríguez et al. CANCER LETTERS
- Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
- (2019) Xiaolong Liu et al. BIOLOGICAL PROCEDURES ONLINE
- Mechanisms of ERBB3 Action in Human Neoplasia
- (2019) Laurel Black et al. AMERICAN JOURNAL OF PATHOLOGY
- A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
- (2019) Yuuri Hashimoto et al. CLINICAL CANCER RESEARCH
- U3-1402, a novel HER3-targeting antibody-drug conjugate, for the treatment of Colorectal Cancer
- (2019) Shigehiro Koganemaru et al. MOLECULAR CANCER THERAPEUTICS
- ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
- (2019) Nicolas Kiavue et al. ONCOGENE
- Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms
- (2019) Carla Ríos-Luci et al. CANCER LETTERS
- U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation
- (2019) Koji Haratani et al. JOURNAL OF CLINICAL INVESTIGATION
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to Antibody–Drug Conjugates
- (2018) Sara García-Alonso et al. CANCER RESEARCH
- Clinical development of HER3-targeting monoclonal antibodies: Perils and progress
- (2018) Wolfgang Jacob et al. CANCER TREATMENT REVIEWS
- EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma
- (2018) Emily Capone et al. JOURNAL OF CONTROLLED RELEASE
- Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.
- (2018) Takahiro Kogawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
- (2018) Alberto Ocaña et al. Oncotarget
- An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
- (2018) Kimio Yonesaka et al. ONCOGENE
- An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
- (2017) Luis J Schwarz et al. JNCI-Journal of the National Cancer Institute
- EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma
- (2017) Emily Capone et al. Oncotarget
- An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
- (2017) Luis J Schwarz et al. JNCI-Journal of the National Cancer Institute
- Targeting the EGF/HER Ligand-Receptor System in Cancer
- (2016) Azucena Esparís-Ogando et al. CURRENT PHARMACEUTICAL DESIGN
- Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye
- (2016) Nidhi Nath et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- HER-3: hub for escape mechanisms
- (2015) Emily Capone et al. Aging-US
- PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer
- (2015) Ian J. Majewski et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node
- (2015) S Seoane et al. ONCOGENE
- ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)
- (2015) Pramudita R. Prasetyanti et al. Oncotarget
- Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
- (2015) Juan Carlos Montero et al. Oncotarget
- Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
- (2015) Nadège Gaborit et al. Human Vaccines & Immunotherapeutics
- Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy
- (2014) Josep Lluís Parra-Palau et al. JNCI-Journal of the National Cancer Institute
- Targeting of erbB3 receptor to overcome resistance in cancer treatment
- (2014) Jian Ma et al. Molecular Cancer
- EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo
- (2014) Gianluca Sala et al. Translational Oncology
- Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
- (2013) G. D. L. Phillips et al. CLINICAL CANCER RESEARCH
- Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
- (2013) Ethan V. Abel et al. JOURNAL OF CLINICAL INVESTIGATION
- Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
- (2012) J. T. Garrett et al. CLINICAL CANCER RESEARCH
- Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
- (2011) Howard A. Burris et al. Clinical Breast Cancer
- Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications
- (2011) M. Sánchez-Martín et al. INTERNATIONAL JOURNAL OF CANCER
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling
- (2011) G Sala et al. ONCOGENE
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multichromatic phenotyping of HER receptor coexpression in breast tumor tissue samples using flow cytometry-Possibilities and limitations
- (2010) Arabel Vollmann-Zwerenz et al. CYTOMETRY PART A
- Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells
- (2010) Samuel Seoane et al. JNCI-Journal of the National Cancer Institute
- Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells
- (2009) M. Narayan et al. CANCER RESEARCH
- Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells
- (2008) A. Esparis-Ogando et al. ANNALS OF ONCOLOGY
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started